INmune Bio, Inc. (NASDAQ:INMB) Receives $18.00 Consensus PT from Analysts

Shares of INmune Bio, Inc. (NASDAQ:INMB) have received an average rating of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $18.00.

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of INmune Bio in a research report on Wednesday, October 8th. Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th.

Institutional Trading of INmune Bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its holdings in INmune Bio by 19.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 41,320 shares of the company’s stock worth $323,000 after purchasing an additional 6,654 shares in the last quarter. Nuveen LLC acquired a new position in shares of INmune Bio during the 1st quarter valued at $129,000. Focus Partners Advisor Solutions LLC raised its stake in shares of INmune Bio by 321.2% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 48,813 shares of the company’s stock worth $113,000 after buying an additional 37,224 shares in the last quarter. PFG Investments LLC acquired a new stake in shares of INmune Bio in the second quarter valued at $27,000. Finally, PharVision Advisers LLC bought a new position in INmune Bio during the first quarter valued at about $135,000. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Stock Performance

Shares of INMB opened at $1.80 on Tuesday. INmune Bio has a 1 year low of $1.38 and a 1 year high of $11.64. The firm has a fifty day moving average of $1.75 and a 200-day moving average of $2.58. The company has a market cap of $47.87 million, a price-to-earnings ratio of -0.85 and a beta of 0.91.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, October 30th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.07. Analysts predict that INmune Bio will post -2.24 EPS for the current year.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.